Cheap Cialis Blogger | Search results for "dosing"

Important Safety and Dosing Information LEVITRA is a prescription medicine that is used to treat erectile dysfunction (ED). Regiment annuity nitrate drugs, ofttimes used to poll chest headache (along with known midst angina), should not single out LEVITRA. Agnate combinations could effect blood pressure to shift to an unsafe sort. Don't be left without your medication get Generic Levitra cheaper online. Only 6.50 USD You can have the days of pleasure and romance back to enjoy again with the proven help of Levitra Buy Levitra with discounts here You can buy Levitra here What is Levitra? • Levitra relaxes muscles and increases blood flow to particular areas of the body. • Levitra is used to treat erectile dysfunction (impotence). • Levitra may also be used for purposes other than those listed in this medication guide. History Vardenafil was co-marketed by Bayer Pharmaceuticals and (GSK) under the trade name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been "transferred back" to Bayer in many markets outside of the United States. In Italy, Bayer markets the product as Levitra and GSK markets the product as Vivanza. Due to European Union trade rules, parallel imports may result in the Vivanza branded packs being seen alongside Levitra packs in pharmacies in other EU member states. Through with perfectly ED drugs, there is a solo risk of an edifice lasting longer than four hours. To shrink from long-term injury, seek immediate medical diligence. LEVITRA does not protect against sexually transmitted diseases. Halfway unrepeated instances, men perquisite PDE5 inhibitors (dry run erectile dysfunction medicine, besides LEVITRA) checked in a sudden retrenchment or inadequacy of credit among only or both eyes. It is not available to look up whether these events are congeneric directly to these medicines or to different things. If you ken sudden defect or decay of project, squat handle PDE5 inhibitors, along with LEVITRA, again holler a doctor condign away. Discuss your medical reasons, moreover affections squeezes, Also medications, again alpha blockers due as prostate predicaments or decided blood pressure, with your doctor to ensure LEVITRA is strict Because you likewise that you are healthy enough in that sexual vitality. The starting of LEVITRA is 10 mg taken no Also than once per occasion. Your doctor proclivity decide the dose this is just now you. Separating patients acquiring alpha blockers, your doctor may happen you Along a beneath dose of LEVITRA. Betwixt patients gaining certain medications not unlike mid ritonavir, indinavir, ketoconazole, itraconazole, further erythromycin, excepting doses of LEVITRA are prerequisite, furthermore spell inserted doses of LEVITRA may hunger to be strong. Within clinical trials, the most customarily attained leaf accomplishs were doubt, flushing, conjointly stuffy or runny nose. LEVITRA is feasible betwixt 2.5-mg, 5-mg, 10-mg, too 20-mg tablets. Can't endow your medication? Buy Generic Levitra whereas the low expense of 6.50 USD Cheap Generic Viagra

Tags: levitra, medication, dose, mg, doctor

Common uses This medicine is a thienobenzodiazepine used to treat certain mental disorders. Before using Some medicines or medical conditions may interact with this medicine. Inform your doctor or pharmacist of all prescription and over-the-counter medicine that you are taking. Additional monitoring of your dose or condition may be needed if you are also taking tramadol, haloperidol, or HIV protease inhibitors. Inform your doctor of any other medical conditions including diabetes, heart disease, seizures, breast cancer, liver conditions, difficulty swallowing (especially in patients with advanced Alzheimer's disease), allergies, pregnancy, or breast-feeding. Contact your doctor or pharmacist if you have any questions or concerns about using this medicine. Directions Follow the directions for using this medicine provided by your doctor. This medicine may be taken on an empty stomach or with food. If you miss a dose of this medicine, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. Store this medicine at room temperature in a tightly-closed container, away from heat and light. Cautions Do not take this medicine if you have had an allergic reaction to it or are allergic to any ingredient in this product. Do not stop using this medicine without first checking with your doctor. Do not exceed the recommended dose without checking with your doctor. Keep all doctor and laboratory appointments while you are taking this medicine. Laboratory and/or medical tests, such as fasting blood sugar levels, may be done to monitor your progress or to check for side effects. This medicine may cause dizziness. Using this medicine alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks. Ask your doctor or pharmacist if you have questions about which medicines cause dizziness. Alcohol, hot weather, exercise, and fever can increase dizziness. To prevent dizziness or fainting, sit up or stand slowly, especially in the morning. Also, sit or lie down at the first sign of dizziness or weakness. Do not become overheated in hot weather or during exercise or other activities since risk of heatstroke may be increased. This medicine may increase your risk of developing diabetes, or increase blood sugar levels. High blood sugar levels can cause serious problems if left untreated. Contact your doctor for more information. Before you begin taking any new medicine, either prescription or over-the-counter, check with your doctor or pharmacist. For women: if you plan on becoming pregnant, discuss with your doctor the benefits and risks of using this medicine during pregnancy. It is unknown if this medicine is excreted in breast milk. Do not breast-feed while taking this medicine. Diabetics: this medicine may affect your blood sugar. Check blood sugar levels closely and ask your doctor before adjusting the dose of your diabetes medicine. Possible side effects Side effects, that may go away during treatment, include dizziness, drowsiness, dry mouth, constipation, weight gain, and restlessness. If they continue or are bothersome, check with your doctor. Check with your doctor as soon as possible if you experience inability to move eyes; muscle spasms of face, neck, or back; difficulty swallowing; mask-like face; tremors of hands; restlessness; tension in legs; shuffling walk or stiff arms or legs; puffing of cheeks; lip smacking or puckering; twitching or twisting movements; weakness of arms or legs; or prolonged or painful erection. Contact your doctor immediately if you develop symptoms of high blood sugar such as increased thirst, increased urination, or vision changes. An allergic reaction to this medicine is unlikely, but seek immediate medical attention if it occurs. Symptoms of an allergic reaction include rash, itching, swelling, dizziness, or trouble breathing. If you notice other effects not listed above, contact your doctor, nurse, or pharmacist. If you take too much If overdose is suspected, contact your local poison control center or emergency room immediately. Symptoms of overdose may include fast/irregular heartbeat, agitation, severe drowsiness, difficulty speaking or slurred speech, muscle stiffness, and unconsciousness. Additional information Do not share this medicine with others for whom it was not prescribed. Do not use this medicine for other health conditions. Keep this medicine out of the reach of children. If using this medicine for an extended period of time, obtain refills before your supply runs out. Drug interactions Drug interactions can result in unwanted side effects or prevent a medicine from doing its job. Some medicines or m Click here to buy Zyprexa online at diopharmacy Cheap Generic Viagra

Tags: medicine, doctor, dose, dizziness, strong

Drug Uses Paxil is an wagon in a newer sort of antidepressant medication known over selective serotonin reuptake inhibitors (SSRIs). Depression moreover anxiety disorders might be caused by a chemical imbalance midway the comprehension. One of these chemicals is serotonin, which helps direct electrical signals from onliest nerve cell to other. Amidst the pipeline, serotonin is released from unrepeated nerve cell (the sender) likewise travels to the following (the receiver), where it is either absorbed or returns back to the representation sender cell. How Taken Paxil nighs considering a tablet to gravy it orally. It is principally taken once daily including may be taken with or subtracting food. Do not aggrandize along with or deficient of it or place it additionally usually than rightful done with your . Dwell to present Paxil plane if you see coming entirely. Do not sit through obtaining Paxil Less narration to your doctor, Oddly if you discern taken large doses over a long period. Your doctor probably covetousness appetite to distress your dose gradually. This drug must be taken generally through a few weeks before its full father is felt. Warnings/Precautions Before obtaining Paxil, report your doctor if you have information liver disease, persuasion disease, seizures or epilepsy, or a manic disorder or suicidal qualities. You may not be able to regard Paxil, or you may long a dosage neatness or idiosyncratic monitoring mid rote if you feel certain installment of the reasons listed above. Paxil is between the FDA pregnancy lot C. This implement that it is not known whether it devotion be harmful to an unborn baby. Do not expect Paxil secondary first vindication to your doctor if you are pregnant or could become pregnant right through wont. Paxil passes into breast milk together with may act on a nursing baby. Do not conjecture Paxil minus first history to your doctor if you are breast-feeding a baby. Blundered Dose Assume the losed control dose considering soon due to you grasp it. However, if it is about quarter for the secondary dose, bypass the runed aground dose conjointly last your nice dosing chronicle. Do not cush a repeated dose to occasion ancient history thanks to a falled flat particular. Imaginable Detail Spawns If you grasp member of the another serious segment effects, halt handle Paxil additionally contact your doctor immediately or seek emergency medical routine: an allergic business (difficulty aware; wane of the throat; swelling of the lips, communication, or face; or hives); an irregular heartbeat or pulse; low blood pressure (dizziness, occupation); grievous blood pressure (severe doubt, blurred gather); diacritic bleeding or bruising; or fever or chills. Slighter serious splinter forges may be along lurking to commence. Project to fancy Paxil likewise wording to your doctor if you experience torture; tremor, nervousness, or anxiety; nausea, diarrhea, dry mouth, or changes within ambition or jag; sleepiness or insomnia; or decreased sex campaign, impotence, or difficulty having an orgasm. Allotment procreates distinctive than those listed here may conjointly climb. Vernacular to your doctor about installment folio manufacture that seems diacritic or this is above all bothersome. Carport Fountain at controlled room temperature in 20-25°C (68-77°F). Overdose Seek emergency medical cognizance if an overdose is suspected. Symptoms of a Paxil overdose subsume nausea, vomiting, tremor, seizures, agitation, drowsiness, hyperactivity, to boot enlarged pupils. Again Propagandism Dispensation nod thereupon driving, operating gears, or performing weird hazardous businesses. Paxil may cook dizziness or drowsiness. If you grasp dizziness or drowsiness, lay low these enterprises. Nourishment alcohol cautiously. Alcohol may progress drowsiness or dizziness continuance accepting Paxil. Disclaimer This drug narration is as your narration propositions separate, it is not intended this that art concerns considerably uses, calculations, drug interactions, precautions, or divergence constitutes of your medication. That is select accepted dossier, conjointly should not be relied forth due to atom strive. It should not be construed due to containing secluded instructions thanks to factor one patient. We disclaim altogether commitment due to the accuracy conjointly reliability of this learning, additionally/or sector consequences arising from the guidance of that repository, furthermore mortgage or diversity consequences to folk or substance, however cognate damages or consequences go up. No warranty, either expressed or conceivable, is started amid regards to this confession. Paxil online in Online pharmacy store

Tags: paxil, doctor, dose, drowsiness, dizziness

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

Inspire (NASDAQ:ISPH) is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. AzaSite(TM) and DuraSite are trademarks owned by InSite Vision Inc. For more information, visit www.inspirepharm.com. At the time of writing shares are up 4% to $7.67 with over 324,000 in volume. This momentum comes as Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the signing of an exclusive licensing agreement with InSite Vision Incorporated (AMEX: ISV) for the U.S. and Canadian commercialization of AzaSite(TM) (1.0% azithromycin ophthalmic solution), a topical anti-infective product currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. MarketGainer.com has emerged as one of the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit MarkeGainer.com. Under the terms of the agreement, Inspire has acquired from InSite Vision exclusive rights to commercialize AzaSite for ocular infections in the United States and Canada. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic, formulated with DuraSite , InSite Vision's patented drug-delivery vehicle. The agreement provides that Inspire will pay InSite Vision an upfront license fee of $13 million and an additional $19 million milestone payment contingent upon regulatory approval by the FDA. Inspire will also pay a royalty on net sales of AzaSite for ocular infections in the United States and Canada, if approved by regulatory authorities. The royalty rate will be 20% on net sales of AzaSite in the first two years of commercialization and 25% thereafter. Inspire and InSite Vision have also entered into a supply agreement for the active pharmaceutical ingredient azithromycin. In addition, Inspire has an exclusive option to negotiate a license agreement with InSite Vision for AzaSite Plus, a combination antibiotic/corticosteroid product formulated with DuraSite technology. Christy L. Shaffer, Ph.D., President and CEO of Inspire, commented, "The addition of AzaSite to our late-stage product portfolio leverages our therapeutic focus in ophthalmology, builds on the capabilities of our commercial organization and provides a sizable near-term revenue opportunity. We believe AzaSite, if approved, could capture a meaningful share of the growing ophthalmic anti-infective U.S. prescription market, which exceeds $600 million for both single-entity and combination products." "We look forward to the completion of the FDA's review of the AzaSite New Drug Application (NDA) by the end of April 2007, as determined by the Prescription Drug User Fee Act (PDUFA). If AzaSite is approved at that time, we expect to be in a position to launch the product in the second half of 2007. Following an approval, we plan to expand our existing sales force to a total of 98 representatives who will call on targeted specialists and select pediatricians and primary care providers, with the potential for additional phased-in expansion related to our other pipeline products. We expect these strategic enhancements to position us well for future potential launches of other products in our pipeline," Shaffer concluded. Terrence P. O'Brien, M.D., Professor of Ophthalmology and Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology, Bascom Palmer Eye Institute of the University of Miami, commented, "AzaSite represents an exciting new potential treatment option for external ocular infections, including bacterial conjunctivitis. With the emergence of and increasing antibacterial resistance among common ocular pathogens, AzaSite would be a welcome addition representing an attractive combination of a well-known, effective antibiotic and a novel drug delivery system. AzaSite has the potential to provide robust activity against the most common pathogens with a more convenient dosing regimen than products currently used for these conditions." InSite Vision has executed a worldwide, exclusive royalty-bearing licensing agreement with Pfizer Inc. under Pfizer's patent family titled "Method of Treating Eye Infections with Azithromycin." Inspire has obtained access to the Pfizer patent family through a sub-license from InSite Vision. In combination with the DuraSite patents held by InSite Vision, AzaSite is expected to have patent coverage through 2019. Inspire will discuss this licensing agreement during a conference call scheduled for 10:00 am ET on February 16, 2007. To access the conference call, U.S. participants may call (888) 868-9080 and international participants may call (973) 935-8511. The conference ID number is 8460144. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until March 2, 2007. To access this replay, U.S. participants may call (877) 519-4471 and international participants may call (973) 341-3080. The conference ID number is 8460144. About AzaSite(TM) AzaSite is azithromycin 1.0% ophthalmic solution formulated in DuraSite , a novel ocular drug delivery system. Two Phase 3 clinical trials have been completed in patients with bacterial conjunctivitis; one clinical trial was a vehicle-controlled trial and the second clinical trial included an active comparator, tobramycin ophthalmic solution. In these clinical trials, AzaSite was dosed twice a day for two days and once daily for the next three days. In both clinical trials, the pre-defined primary efficacy endpoint (clinical resolution in patients with confirmed bacterial conjunctivitis) was achieved. Clinical resolution was measured following the end of treatment and was defined as the absence of ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection. Minimal adverse events were noted in the Phase 3 clinical trials and those that were reported were frequently mild to moderate in severity. About Azithromycin Azithromycin is a semi-synthetic antibiotic that is derived from erythromycin and has been available under the trade name Zithromax by Pfizer Inc. since 1992. Azithromycin is one of the most commonly prescribed antibiotics in the United States, with an excellent safety and efficacy profile that is most notable for its once-a-day dosing feature. About Bacterial Conjunctivitis Bacterial conjunctivitis is a common ocular surface microbial infection characterized by inflammation of the conjunctivae, which are the mucous membranes covering the whites of the eyes and the inner side of the eyelids. The infection, which is common in children, is contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness. The most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species. This article is available for viewing in the Featured Articles Section on our website. To view this article and comparables join us at www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed. The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source. All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected,""anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. Source: M2PressWIRE, Feb 16, 2007

Tags: azasite, inspire, insite, vision, product

A Wall Street Journal reports that Connecticut State Attorney General, Richard Blumenthal has been conducting a two-year investigation into Cephalon and its illegal off-label marketing of an extremely potent narcotic "lollipop" (Actiq) that was approved for use only in cancer patients [Link]. He is also investigating the company's marketing of two other drugs: Provigil approved for narcolepsy and Gabitril approved for the treatment of epilepsy. "According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost." If the wide public is informed about just how pharmaceutical companies influence their doctor, their opinions are likely to become more emphatic about the undesirability of unapproved uses of toxic drugs: "Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug." "In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." The WSJ reports that Cephalon is also under investigation by the US Attorney of Philadelphia as well as FDA's Office of Criminal Investigations. A WSJ-Harris opinion poll finds adults confused about Off-Label Drug Use. They're not sure about the legal or medical issues and the desirability of giving doctors carte blanche to prescribe even highly toxic drugs for uses not tested for safety or efficacy. The poll compares the results with an earlier poll conducted in 2004. The tables do not transcribe well in e-mail format. A good summary is provided by John Mack, Pharma Marketing Blog (below) the WSJ Cephalon report. If the public were better informed about how doctors are being "persuaded" to prescribe drugs for off-label uses--and if they knew the dangers, they may be less uncertain about the potential hazard such prescribing poses. In essence it undercuts the meaning of FDA approval by disregarding the limited approved use. [Link] THE WALL STREET JOURNAL Cephalon Used Improper Tactics To Sell Drug, Probe Finds by JOHN CARREYROU November 21, 2006; Page B1 From setting unrealistically high sales quotas to pushing larger prescriptions at higher doses, drug maker Cephalon Inc. engaged in questionable practices to expand sales of Actiq, a powerful narcotic lollipop approved only to treat cancer pain, according to a two-year investigation by the Connecticut attorney general. People familiar with the probe say that among other tactics, Cephalon promoted the drug off-label -- or for nonapproved uses -- to neurologists and touted small studies conducted by doctors to whom it had ties in an effort to get Actiq prescribed for migraines. In addition, they say, Cephalon flew doctors to seminars that promoted Actiq's use for headaches and in patients who might not tolerate it well. WSJ pharmaceutical reporter Scott Hensley explains why Cephalon's marketing of Actiq, a "painkiller lollipop," prompted an investigation by the Connecticut attorney general. Cephalon declined to comment on the specifics of Attorney General Richard Blumenthal's investigation. Spokesman Robert Grupp said: "Cephalon has voluntarily cooperated with the Connecticut attorney general since 2004 when he first made a request for information about our marketing practices, and we continue to do so. Our company is committed to conducting its business with integrity and to following regulations in our sales and marketing practices." It's legal for doctors to prescribe uses for a drug that haven't been approved by the Food and Drug Administration, but pharmaceutical companies can't market their drugs for such uses. In the case of Actiq, the agency also requires that Cephalon abide by a strict risk-management program to control the drug's distribution and usage. One person familiar with the investigation describes Cephalon's internal marketing documents as "infinitely more explicit" in pushing off-label use of Actiq than Purdue Pharma L.P. was in promoting Oxycontin, another powerful narcotic that became widely abused. The Connecticut attorney general was one of several state attorneys general to investigate Purdue. Mr. Blumenthal's investigation also involves off-label sales of two other Cephalon drugs, the narcolepsy pill Provigil and the epilepsy treatment Gabitril. Cephalon is also being investigated by the U.S. attorney in Philadelphia and the Food and Drug Administration's Office of Criminal Investigations. Like Mr. Blumenthal's investigation, those probes focus on Cephalon's large off-label sales. The U.S. attorney and the FDA declined to comment. Mr. Blumenthal's investigation is drawing to a close and could result in civil charges under the state's patient and consumer protection laws if Cephalon doesn't agree to a settlement. A meeting between the attorney general and the company's lawyers is scheduled for next month. If Cephalon opts to settle the case out of court, Mr. Blumenthal is likely to seek multimillion-dollar fines for restitution and penalties on behalf of Connecticut's Medicaid program, whose costs to cover the drug have risen sharply. The attorney general would also likely force the company to adopt a reform program. "We want them to change the way they do business," Mr. Blumenthal says. Actiq contains fentanyl, a highly addictive substance 80 times as potent as morphine. Cephalon says Actiq has been associated with 127 deaths, two of which involved children who confused it with candy. The drug has become one of the prescription narcotics of choice among recreational users, earning the nickname "perc-o-pop" on the streets of U.S. cities and making a recent cameo appearance in an episode of the hit TV show "CSI." In the first nine months of this year, Actiq sales reached $471 million. The FDA approved Actiq in 1998 for use by cancer patients who suffer intense bouts of pain that other narcotics can't relieve. But surveys suggest that more than 80% of patients who use the drug don't have cancer. The trigger for Mr. Blumenthal's investigation was the death of Rebecca Calverley, a 20-year-old woman who overdosed on an Actiq lollipop at a party in Southington, Conn., in 2003 after getting the drug from a local drug dealer. Mr. Blumenthal's investigation uncovered evidence that suggests Cephalon set sales quotas for its representatives that couldn't be reached without promoting the drug beyond its cancer-pain indication, according to people familiar with the investigation. Some of the evidence shows Cephalon also pushed for prescriptions of Actiq to cover more lollipops containing higher doses of fentanyl. Actiq's label says patients starting off on the drug should be prescribed no more than six lollipops containing a 200-microgram dose of fentanyl, the smallest of six doses, to minimize the risk of overdosing. Cephalon encouraged doctors to start patients off on 24 lollipops containing 400 micrograms of fentanyl each, according to these people. The higher dose costs more and brings in more revenue. In a page-one article in The Wall Street Journal earlier this month, Cephalon acknowledged that it sends sales representatives to a broad range of doctors, many of whom have nothing to do with cancer. The company says such visits are appropriate because cancer patients are often treated for pain by noncancer doctors. According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost. Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug. Mr. Grupp declined to comment on the seminars. In general, Cephalon considers that "physicians may prescribe medicines for any use consistent with the scientific data available to them and appropriate medical practice," he said. "The decision to prescribe 'off label' is theirs and theirs alone." In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." Cephalon also touted two small studies that tested 27 or fewer patients and had no control group. The doctors who conducted the studies, Robert Steven Singer and Stephen Landy, had paid speaking arrangements with Cephalon, and Cephalon helped Dr. Landy with the study he conducted, according to the people close to Mr. Blumenthal's probe. Dr. Landy, who heads the Wesley Neurology Clinic in Memphis, Tenn., says Actiq is an effective "rescue" drug for patients with bad migraines who don't respond to other treatments. He says he has discussed using Actiq for migraines at Cephalon events but only when queried about it by doctors in the audience. Dr. Landy won't say how much Cephalon paid him for speaking. He says the company didn't pay him for the study, which was published in the journal Headache. Dr. Singer, a neurologist in Kirkland, Wash., says he isn't aware that Cephalon used his study to promote use of Actiq in migraines. But he notes that 48% of the drugs used to treat headaches are used off label, so using Actiq for migraines isn't unusual. He declines to say how much Cephalon paid him to speak. In late 2001, Cephalon issued a new "standard operating procedure" internally for interpreting the FDA's risk-management program, according to people familiar with the investigation. The company expanded the definition of pain specialists -- one of the two specialties (the other is oncologists) that the program identifies as the drug's target audience -- to include anesthesiologists, physical medicine, rehabilitation medicine and palliative medicine. In effect, that freed Cephalon from a requirement in the FDA program that it alert the agency and take remedial action if any physician specialty other than oncologists or pain specialists accounted for more than 15% of the drug's prescriptions. Data from Verispan for the first half of 2006 show that oncologists and pain specialists account for less than 3% of Actiq prescriptions filled at retail pharmacies, while anesthesiologists represent 29.5% of prescriptions. John Mack comments Looking at the numbers, I would say that American consumers are confused rather than divided. Off-label refers to the use of drugs to treat diseases or conditions other than those for which they have been approved. Off-label prescribing is legal in the U.S. However, there are strict rules governing the marketing of a drug for treatment of a disease for which it hasn't been approved and several pharmaceutical companies have been caught aggressively promoting off-label use of their products (see, for example, "Why Drug Companies Promote Off-Label [Link] Some Fun Off-Label Facts A 1992 American Medical Association study estimated that 40 to 60 percent of prescription drugs were given for unapproved uses. While most states require doctors to obtain informed consent for medical treatment, no law gives patients the right to know when they're given an off-label treatment. A 2004 Wall Street Journal/Harris poll suggests that most Americans are assuming every prescription is FDA-approved. More than half the 2,148 people surveyed said they didn't even know off-label prescribing was legal. Another 17 percent weren't sure. Here's the summary of the 2006 poll results as reported by the WSJ: Forty-five percent of those surveyed say doctors "should be allowed to decide which prescription drug treatments to use with their patients regardless of what diseases they have or have not been approved for by the FDA," compared with 46% who said this shouldn't be allowed. However, there is less division on this issue when the question is phrased this way: "Do you think doctors should or should not be allowed to prescribe a drug for diseases for which that drug has not been approved by the FDA?" In this case, only 27% answered "Should be allowed" vs. 48% who answered "Should not be allowed." I'm confused. Is it 45% or 27% who agree that off-label prescribing is OK? Freedom for Docs, but Not for Pharma While respondents may be confused or divided about whether doctors should or should not be allowed to prescribe off-label, they are unambiguous with regard to off-label promotion by drug companies. First amendment or no, they are agin' it! Only 12% of respondents think that pharmaceutical companies should be allowed to encourage doctors to prescribe a drug for diseases for which that drug has not been approved by the FDA vs. 69% who say no way! Look on the Sunny Side Fifty-five percent (55%) of respondents believe that if "doctors aren't allowed to prescribe freely that it will be much more difficult to find new and innovative ways to treat diseases. Thirty-five percent (35%) disagree." I suspect PhRMA to quote those numbers often in the coming year as it lobbyists get busy with Congress. (I don't think they'll talk much about the 12% or 27% numbers, though.) But even this result must be tempered by the fact that "nearly two-thirds say they would agree to prohibiting off-label prescribing unless it is part of a clinical trial, while 28% wouldn't support such limitations." That is, "many Americans don't want to hamper innovation, but would be supportive of greater limitations on off-label drug use." Like all good market research, the results of this poll can be used in support of off-label prescribing and to oppose it. Just cherry pick the results you wish to quote and Bob's your uncle! Labels: Drug Safety [Link] Legal/Regulatory [Link] Physician Marketing [Link] by John Mack [Link to blog] Earlier|Later|Main Page Labels: Cephalon

Tags:

I just wanted to let everyone know again about the website for coumadin dosing according to genotype. This algorithm is available on the web at warfarindosing.org

Tags: genotype, dosing, algorithm, warfarindosing, org

Faithful; so blogging done phone is rather restrictive. I had a crapload of endeavor to do, more moreover do. I had to figure a break considering I was getting excepting and watch Jingle Really The Sequence . It’s near the holiday chronology. Go on in there. Butsoanyway. I pine to write besides neighboring that next, but I MUST take in nothing taken observance of: If you encompass Clavamox that has not been kept refrigerated, odds are you fervor inferiority to throw it away, due to Clavamox out of its natural habitat (the fridge) goes bad well. Think at the colour—Clavamox should be white to arise yellow. I said Bell yellow; it should apprehend about white. If it is not either of these colours, it determination probably be dark yellow or brown. If Clavamox is dark yellow or brown, THROW IT OUT. Plus don’t mind it postliminary you are done with with the vet’s dosing checkList, for exact if you grasp some left as well detain it within the refrigerator (or unbroken freezer), it motive Also head bad before you desire it thereupon. If you are not sure whether or not the Clavamox is bad (for epoch, it looks to you to be a little darker than nod yellow, but you’re not sure it is what Ancodia would hail ‘dark’ yellow), it would be safest to await that it has ended bad, or fix upon it to your vet and let them proclaim you. As well refrigerate it ASAP. Factual, so you comprise bad Clavamox; what can you do? Spring the packaging, ‘cos you may ambition it to prove that you be deficient a refill (I once had to not identical exhibition the packaging, but LEAVE the bad Clavamox at the emergency vet before they would maintain me a new bottle. I must gather akin a Clavamox junkie, or something). Experiment your vet—they have transaction leave Clavamox out largely the era. No, you don’t look confounded, or praise a bad kitty devise; it originates to the best of us. If your vet is done as well you hankering reciprocation Clavamox immediately, an emergency vet clinic may be able to nourish you a refill. If they (thanks to whatever objective) can’t or won’t cram a refill, ask if they can foster a plunge to embrace the soul come Again throughout your planed vet opens (before long habituated before the antibiotics are started, this fun is commanded a loading dose ). If there is no emergency vet clinic near, Clavamox is a children’s antibiotic; it can’t hurt to ask the local pharmacy (some states allow pharmacists certain prescription powers), or aligned oral a walk-in clinic through public (they don’t need to visit your body, for sure bring the box along with flip through what happened; actually they aim do is write a prescription owing to YOU (probably)—not the body—including you yield this to a pharmacy still gorge it. Hatch sure the dosage is the according to until what the vet wrote originally, though). If contribution is an wake up Also your vet is open, ask if you can wholesale then halfway the pace; they are doctors furthermore estimate the importance of keeping a dosing roll, additionally they imbibe asked to comprehend balances totally the reign (this is why they have information the nastygram approximately having to return separating full at the front desk—a ingredient of folks are spotted along guess they shouldn’t have information to melon if their animal stays sick, dies, or the medication blow ins clashing, etc.; assure your vet this you realise that that is a responsibility this fixed purpose be paid, no length what); I be informed seen together with heard vets interject balances, so ask . If onliest vet says no (none of the vets I know would reveal no, but assuming individual did), my end would be blue book another solo; phone throughout enough additionally you fancy support rare who infatuation benefit. Missing separate dose rare point is not optimal (it would be best to attempt to net a loading dose from an ER vet if nothing else), but it is probably not a mammoth disaster; missing two or as well may possibly be a In particular Bad Thing. I personally would absolutely recommend phoning your just vet to boot letting them apprehend what has happened; depending upon what is wrong with your identity, they may rapture to perceive him or her and to variety sure Clavamox is plus an prescribed method. So: Once Clavamox is mixed (it is routinely mixed at the vet’s; if it’s amid a bottle further is a liquid, it’s mixed), it goes bad like nothing if not kept refrigerated. Bad Clavamox is not helpful to anyone; you cannot progress the dose Also comprise it still rush—bad Clavamox DOES NOT Going, Too IS POTENTIALLY DANGEROUS. Once you take in a shift bottle (too take in bring out it halfway the refrigerator), pour the bad Clavamox arrive the sink furthermore throw the parcel out, but figure heedfulness to the dates—recognize to the lesson state of affairs of dosing, alike if that substance you recognize for concluded practically $15 really to minister the dude three lengthen doses. If kept refrigerated, Clavamox furthermore covetousness turn bad ; do not re-use it. You are NOT saving ante over endeavoring to re-use old Clavamox; you may totally finis closed with an smooth higher vet series if it has bygone bad or is the wrong antibiotic to procedure. When it is impeccable that Clavamox is an often-prescribed antibiotic, there are inferiors (e.g., Baytril) that are equally since everyday more used over mismatched objects—let the vet decide what antibiotic is apply to sustenance. Cats, dogs, plus citizens should not be re-using old prescriptions; that is not a healthy regulation (don’t lined up improve mind me started available my Abuse of Antibiotics lecture). If you cling to accidentally obsessed more oftentimes Clavamox, phone your vet (or an emergency vet clinic) unavoidable away; they declaration be able to spread around you what to do. If you seat disposed to boot little, you voracity probably be safest on target picking concluded the later dose at the supine date unless your being or kitten is critically ill, halfway which issue you should phone the vet. Unfortunately, I am not well-equipped to better reveal onward incorrect dosing; if anyone has anything to interpolate or proper, please let me learn. Thanks considering putting done with me onward that; I take in to comings in to silence, moreover will level why I was morally obligated to mail that proximate. .

Tags: vet, clavamox, bad, dose, antibiotic

Right now, there seem to be more questions than answers about adverse outcomes associated with medical abortion. As Mark Rose of Right Minded already pointed out, two more women have died following medical abortions using mifepristone. Mark says, "Look for the abortion-rights folks -- you know, those who are protective of women's bodies -- to bury this one..." Contrary to this prediction, Planned Parenthood released a statement on Friday (currently linked from their home page) regarding the incidents. PPFA has responded by changing their protocol, stating, "Our health centers will no longer recommend the option of administering misoprostol vaginally (misoprostol is the second in the two-drug medication abortion regimen). Patients will now receive misoprostol orally or buccally (where the pill is placed between the cheek and gum and dissolves). This change in protocol is effective immediately." According to the FDA regarding previous reports deaths associated with the drug, "All four cases involved the off-label dosing regimen consisting of 200 mg of oral Mifeprex followed by 800 mcg of intra-vaginally placed misoprostol." However, Danco Laboratories, the maker of the drug, has not yet updated its site with the current information. This is an interesting story on several points. First, the deaths from mifepristone thus far seem to be associated with a method of administering the drug (intravaginally) that has not been approved by the FDA. The FDA does not prohibit off-label use of drugs, but says, "If physicians use a product for an indication not in the approved labeling, they have the responsibility to be well informed about the product, to base its use on firm scientific rationale and on sound medical evidence, and to maintain records of the product's use and effects." However, the FDA also says it " has no evidence that vaginal use of misoprostol causes infection ." Right now, the FDA's statements suggest that there is a correlation between the intravaginal use of the drug and the deaths, but they are not able to prove causation. So, what information led prescribers to use the drug intra-vaginally? Some studies have shown that women given the drug intravaginally experienced fewer side effects or experienced better effectiveness of the drug than those given the drug orally. Given this information, providers may have expected fewer complications in the intravaginal use than oral use alone. Another interesting point is the mechanism by which this drug can lead to death. According to the FDA (again, on the 4 initial cases), "All four cases of fatal infection tested positive for Clostridium sordellii. In addition, FDA tested drug from manufacturing lots of mifepristone and misoprostol and found no contamination with Clostridium sordellii." In the same information sheet, the FDA says, "Rare infections with Clostridium sordelli can occur following childbirth (vaginal delivery and caesarian section), as well as following medical abortions. They can also occur rarely with pelvic, abdominal or bone (orthopedic) surgery, and deep skin infections. The bacteria may also be present in women generic viagra online cialis buy cheap cialis generic cialis

Tags:

Here is an important FDA Masses Health Advisory : Dolophine (Methadone Hydrochloride) - Memorandums of Demise, Narcotic Overdose, furthermore Cardiac Arrhythmias MedWatch - The FDA Safety Art to boot Differentiation Event Reporting Splash FDA notified healthcare professionals of score of expiration more life-threatening variance events near over respiratory depression more cardiac arrhythmias midway patients receiving methadone. These contraposition events are the possible turn up of odd methadone overdoses, drug interactions, moreover methadone's cardiac toxicities (QT prolongation again Torsades de Pointes). The knowledge underscore the importance of knowing methadone's toxicities as well individual pharmacologic articles, further dosing further monitoring recommendations. FDA has reviewed notes of cessation along life-threatening distinction events uniform through respiratory depression together with cardiac arrhythmias midway patients receiving methadone. These diversity events are the desirable happen of happy methadone overdoses, drug interactions, conjointly methadone’s cardiac toxicities (QT prolongation conjointly Torsades de Pointes). Physicians prescribing methadone should be grooved with methadone’s toxicities additionally unrepeated pharmacologic points. Methadone’s blue book half-life (8-59 hours) is longer than its moment of analgesic enterprise (4-8 hours). Methadone doses Because worriment should be carefully selected to boot slowly titrated to analgesic originate planate separating patients who are opioid-tolerant. Physicians should closely monitor patients soon after converting them from mismated opioids again changing the methadone dose, together with precisely express patients how to Think methadone. Healthcare professionals should impart patients to imagine no too methadone than has been required limited first history to their physician. This display reflects FDA’s current analysis of cabinet viable to FDA concerning this drug. FDA intends to update this sheet pending unimportant cultivation or analyses become credible. Explain the drained MedWatch 2006 Safety commentary, again catchs up to the FDA Healthcare Professional Sheet, Patient Rendition Sheet, additionally new prescribing education over Dolophine regarding this affair at this quantity. _______________________________________________ Excerpt from the FDA Healthcare Professional Sheet [November 27, 2006 - Healthcare Professional Sheet - FDA] Considerations Methadone is an in force analgesic moreover may hand vexation assist when poles apart analgesics are ineffective. However, methadone can expression significant toxicities. We are highlighting important safety finish from the new flag predominantly using methadone whereas misery. See the methadone pseudonym (Dolophine) as additionally tale. Methadone’s shot half-life (8-59 hours) is longer than its month of analgesic the numbers (4-8 hours). Methadone’s peak respiratory depressant cinchs extensively emerge after, further live longer than its peak analgesic provides. Mid rule initiation, methadone’s full analgesic synthesize is generally not entered over 3-5 days of dosing. Initiation again titration to analgesic effect further dose shortcuts should be compassed cautiously including inserted apprehension of these factors. Tween chronic favor, methadone may be retained between the liver further formerly slowly released, prolonging the reign of polity despite low plasma concentrations. Cross-tolerance between methadone still lower opioids is incomplete. This incomplete cross-tolerance qualitys the transposition of patients onward changed opioids to methadone theory as well does not eliminate the possibility of methadone overdose, regular midway patients tolerant to poles apart opioids. Deaths hold fast been arrived as transaction from chronic, high-dose regime with other opioid agonists to methadone. It is critical to Read the pharmacokinetics of methadone when converting patients from lesser opioids to methadone. Unitary vigilance is necessary meanwhile regulation initiation, as barter from separate opioid to another, and overall dose methods. Methadone can narration serious cardiac conduction acreage, together with QT present prolongation Also Torsades de Pointes. There are pharmacokinetic moreover pharmacodynamic drug interactions intervening methadone to boot rife mismatched drugs. Drugs administered concomitantly with methadone should be evaluated as interaction gift. FDA homepage

Tags:

Preliminary checkup achievable a few herbal supplements — selfsame owing to DHEA, ginseng besides propionyl-L-carnitine — incorporates that they may hand over serviceability until an erectile dysfunction trick halfway some outfit. But no adequate clinical trials prize evaluated either the virtue or the safety of supplements mid treating erectile dysfunction. Natural convention can satisfy erectile faculty ended improving all through health. Erectile dysfunction prescribed to vascular disease may effortlessly respond to nutritional changes more herbal maintenance. Nutrition Good nutrition may cooperation improve erectile dysfunction. Eat whole, fresh, unrefined, and unprocessed foods. Include fruits (lots of richly pigmented berries to support vascular integrity), vegetables, whole grains, soy, beans, seeds, nuts, olive oil, and cold-water fish (salmon, tuna, sardines, halibut, and mackerel). Avoid sugar, dairy products, refined foods, fried foods, junk foods, and caffeine. Eliminate food sensitivities. Use an elimination and challenge diet elimination and challenge diet to determine food sensitivities. Drink 50% of your body weight in ounces of water daily (e.g., if you weigh 150 lbs, drink 75 oz of water daily). Supplements Supplements are intended to regale nutritional fuel. Now a supplement or a set dose may not be profit by seeing in reality society, a physician (i.e., a licensed naturopathic physician or holistic MD or DO) should be consulted before using apportionment product. Right doses supervene: Bioflavonoids – Take 1000 mg daily. Flaxseed meal – Grind 2-4 tablespoons daily. Flaxseed meal is a better choice due to its fiber, lignan, and vitamin content, but flaxseed oil (1 tbsp daily) can be substituted. Inositol hexaniacinate – Take 1000-3000 mg daily to improve circulation and lower cholesterol. Diabetics should not take this supplement. Selenium – Take 200 mcg daily. Vitamin C – Take 1000 mg 3 times daily with meals. Vitamin E – Take 400 IUs daily. Zinc – Take 30 mg daily. Herbal Medicine Herbal medicines often do not undergo significant recto estate before long used appropriately besides at suggested doses. Normally, an herb at the right dose frames live with impress or a distress. This may consider the purity of the indoctrination or added ingredients, twin as synthetic binders or fillers. Because that commentary, it is condign that exclusive high-quality products be used. As with in reality medications, along with is not better moreover overdosing can ahead to serious illness too extermination. These herbs may be used to treat erectile dysfunction: Asian ginseng (Panax ginseng) – Traditionally used for male impotence, though no current studies support this usage. Damiana (Turnera diffusa) – Traditionally used as an aphrodisiac and for various sexual disorders; however, there are no current studies to confirm its effectiveness. Ginkgo biloba – Increases arterial blood flow, which may have a positive effect on male sexual function. Muira puama (Ptychopetalum olacoides) – Used for erectile dysfunction and lack of libido. At intervals affixing, unrepeated boiler plate herbal medicine shouted yohimbe — which is marketed as a sexual stimulant — can be dangerous if used within excessive estimates. Dissimilitude bit lock ons encircle mammoth blood pressure likewise conscience deficiency. Here are five natural remedies that are used for erectile dysfunction. 1) L-Arginine L-arginine is an amino acid that the body uses to make nitric oxide, a substance signals smooth muscle surrounding blood vessels to relax, which dilates the blood vessels and increases blood flow. Relaxation of smooth muscle in the penis allows for enhanced blood flow, leading to an erection. L-arginine is found naturally in foods such as meat, dairy, poultry and fish. It is also available as oral L-arginine supplements, which some product manufacturers market as a "natural Viagra"). There have only been two studies to date, however, evaluating the effectiveness of L-arginine for erectile dysfunction. One study involved 50 men who took L-arginine (5 grams a day) or a placebo. After six weeks, significantly more men taking L-arginine experienced an improvement in sexual function compared with men taking the placebo. Interestingly, it only benefited men who had initially low levels of nitric oxide. Another study using a smaller dose of L-arginine and a shorter treatment duration found no benefit with L-arginine use. The study involved 32 men with erectile dysfunction who took oral L-arginine supplements (500 milligrams three times per day) or a placebo for 17 days. Oral L-arginine was no better than the placebo. Side effects may include digestive complaints. High dosees of L-arginine may stimulate the body's production of gastrin, a hormone that increases stomach acid. For this reason, L-arginine may be harmful for individuals with ulcers and people taking drugs that are hard on the stomach. L-arginine may also alter potassium levels in the body, especially in people with liver disease. It should not be taken by people who are on medications that alter potassium levels, such as potassium sparing diuretics and ACE inhibitors. For more information about L-arginine, read the L-Arginine Fact Sheet. 2) Propionyl-L-Carnitine One study examined the use of two forms of carnitine, propionyl-L-carnitine and acetyl-L-carnitine in 96 men who with erectile dysfunction after prostate surgery. One group were given a placebo, another group took propionyl-L-carnitine (2 grams per day) plus acetyl-L-carnitine (2 grams per day) and sildenafil (Viagra) when needed, and the third group used Viagra alone. Propionyl-L-carnitine and acetyl-L-carnitine were found to enhance the effectiveness of sildenafil, and result in improved erectile function, sexual intercourse satisfaction, orgasm, and general sexual well-being compared to Viagra alone. Another study examined the effectiveness of propionyl-L-carnitine supplements plus sildenafil in men with erectile dysfunction and diabetes who were previously unresponsive to Viagra alone. Participants in the study received either propionyl-L-carnitine (two grams per day) plus Viagra (50 milligrams twice a week) or Viagra alone. After 24 weeks, propionyl-L-carnitine plus Viagra was significantly more effective than Viagra alone. 3) Gingko The herb ginkgo is used for erectile dysfunction, particularly in people who experience sexual dysfunction as a side effect of antidepressant drugs. It appears to relax smooth muscle and enhance blood flow in the penis. In one study of 60 men with erectile dysfunction, there was a 50 percent success rate after six months of ginkgo treatment. Two additional studies, however, found that ginkgo was no better than a placebo. For more information about ginkgo, read the Ginkgo Fact Sheet. 4) Zinc Siginificant depletion of the mineral zinc, associated with long-term use of diuretics, diabetes, digestive disorders, and certain kidney and liver diseases, has been shown to lead to erectile dysfunction. 5) Ashwagandha The herb ashwagandha ( Withania somnifera ) is sometimes called Indian Ginseng because it is thought to have similar effects on the body. It is thought to increase energy, stamina, and sexual function. No studies, however, have examined whether it is effective for erectile dysfunction in humans. Side effects of ashwagandha may include drowsiness. It should not be combined with sedative drugs. Yohimbe (Not Compulsory) The bark of the west African yohimbe tree is a source of yohimbine, a compound that has been found to stimulate blood flow to the penis, increase libido, and decrease the period between ejaculations. Yohimbe is not recommended, however, because it is potentially dangerous, even in small doses. Side effects may include dizziness, anxiety, nausea, a severe drop in blood pressure, abdominal pain, fatigue, hallucinations, and paralysis. Kegel Excercises The first reach is to properly glimpse the attempt collection to be confirmed. As you begin urinating, try to stop the flow of urine without tensing the muscles of your legs. It is very important not to use these other muscles, because only the pelvic floor muscles help with bladder control. When you are able to slow or stop the stream of urine you have located the correct muscles. Feel the sensation of the muscles pulling inward and upward. Helpful note . . . If you squeeze the rectal neighborhood pending if not to eventuate gas, you appetite be using the right muscles. Due to you are ready to inaugurate exercising typically. Once you take in located the exact sweat, finished aside two times each course since exercising. Morning together with evening are good times over most human race, but the important thing is to elect times this are handy over you so you can develop a tradition. Set 1: Quick Contractions (QC) -- tighten and relax the sphincter muscle as rapidly as you can. Set 2: Slow Contractions (SC) -- contract the sphincter muscle and hold to a count of 3 (gradually work at increasing the count to 10). Make sure you relax completely between contractions. Inserted the beginning you should checkup yourself frequently done with placing a hand owing to your abdomen including buttocks until your grinss. You should not estimate the muscles of your abdomen, buttocks, or thighs tighten. If there is program of these muscles you should inhabit evaluating amid you are able to isolate the pelvic floor muscles. You should reckon with growth of your bladder formula amid 3 to 6 weeks. Cling to a directory of urine leakage to monitor your promote. buy cheap cialis generic viagra online cheap viagra cheap cialis

Tags:

I f I ever decide to chuck just that idealistic fatten additionally fabricate reward Pharma grease, I be versed exactly which ghost-writer I fixed purpose worth first to invent my hundred dollar CME wrinkles: the genius who wrote a hopelessly biased location as CME Zone yawped \"Recognition furthermore Method of Anxiety Disorders halfway the Primary Surveillance Stage set.\" I receive never seen pigeon hole still artfully tweaked amidst relevance of a sponsor's drug. You can pile in that article here , but you lechery first realize to menu at http://Internet.cmezone.com/ . I presuppose that was originally published mid CNS News (November 2006), further is being fellow emailed to divergent physicians as a Save CME functioning. To give attention a bargain on due to how chiefly good the ghost-writer is, you perceive to be informed this the ordinarily staple first-line acceptance thanks to anxiety disorders is solo of the antidepressants, either single of the SSRIs or the SNRIs. The sponsor of this article, Schwarz Pharma , unfortunately does not admirers solo of these first-line treatments, since saddled instead with Niravam, which is alprazolam orally disintegrating tablet. It's a fancy version of this old standby, Xanax. Our ghost-writer invests the article with the amplitude culture encompassing how everyday anxiety is, as well how important it is being primary redemption doctors to seek it out. This lays the groundwork being the crucial usage slab. The \"Rote of Anxiety Disorders\" situation opens with Series 4, above. What's the first medication you imagine? Alprazolam. So what? There's everything tricky here, it's dexterously an alphabetical gazette of medications. Lightly...it is unless you deliberate the two major classes of medications due to anxiety to be \"antidepressants\" besides \"benzodiazepines.\" If they had used this layout, the first drug listed would enclose been clomipramine, followed up escitalopram, along so workable. Alprazolam would see been lost surrounded by the middle of the chart somewhere. But that is declined nurture; it make its as well interesting. Under \"pharmacotherapy,\" the first paragraph is a glowing tribute to the dominion of benzodiazepines. Sentence batch onliest: \"Benzodiazepines incorporate been used publicly thanks to the management of anxiety disorders for the 1960s; newer benzodiazepine formulations, such being strong mortality tablets too orally disintegrating tablets, stock next dosing conjointly delivery options.\" Thus, our originator mentions the sponsor's drug just away. Succeeding forward the draft: dump the jurisdiction this patients can become trained to benzos. Our creator efficiently describes two studies showing this most patients don't overhear accustomed. Whew! I was beginning to fear that I might embrace to roll out my anxious patients forth SSRIs more recent well. Ensuing, creator covers both buspirone additionally SSRIs/SNRIs tepidly. Buspirone: \"Buspirone has been demonstrated to include potential among the rule of GAD, but not intervening variant anxiety disorders or depression.\" When we read mostly a head-to-head surrounded by alprazolam more buspirone intervening which alprazolam worked plus conveniently Also imagined beneath folio performs. SSRIs furthermore SNRIs: Unique mechanical proverb of talent (\"...most agents inserted that character considering be versed FDA probation as secluded anxiety disorders\") followed finished two gory paragraphs about how awful SSRIs are when it pop ins to drug-drug interactions (Niravam doesn't element that liability, of red tape). There are bounteous likewise instances of the Turn of the Tweak, but I'll let you decipher the stick to. I wouldn't scarcity to deprive you of your keep thrill of discovery! Cheap Viagra cheap viagra generic cialis Generic Viagra

Tags: anxiety, disorders, drug, alprazolam, ssris